We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Trial of RF Ablation Plus Drug for Liver Cancer

By HospiMedica staff writers
Posted on 18 Jan 2001
A phase 2 study is evaluating the effectiveness of an immune system enhancer in combination with radio frequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC). More...
HCC accounts for more than 80% of all primary liver tumors and is one of the most prevalent malignancies in the world.

RFA destroys tumors by radio waves delivered via a probe-bearing needle, and is increasingly used to treat primary liver cancer as an alternative to surgical resection or localized chemotherapy. The goal of the current trial is to learn whether the immune system enhancer, Zadaxin, may contribute to the effectiveness of tumor therapy with RFA. Zadaxin is a synthetic peptide that has been used for the treatment of hepatitis B and C. The drug is the product of SciClone Pharmaceuticals (San Mateo, CA, USA).

"We have seen early indications of Zadaxin's effect in combination therapies for other types of cancer such as malignant melanoma, for which trials have recently begun in Australia,” noted Alfred R. Rudolph, M.D., COO of SciClone.


Related Links:
SciClone

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Adhesive
MED 5570U
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.